pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$CRSPCRISPR Therapeutics AG

$CRSP51.42-5.23%
Zug, CHupdated 17d ago

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom.

SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 2: 1
1Phase 2
Phase 2
zugocaptagene geleucel
B-Cell Chronic Lymphocytic Leukemia

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertensionrecruitingn=69
  • phase1A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumorscompletedn=19
  • phase1A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Diseaserecruitingn=80
  • phase2Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Diseaserecruitingn=60
  • —A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapiesenrolling by invitationn=70
  • phase1A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemiasrecruitingn=90
  • phase2A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Diseasenot yet recruitingn=220
  • phase2A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignanciescompletedn=12
🐶 Hiring Signal
No open roles indexed yet — view CRISPR Therapeutics AG jobs →

News

  • Seawolf surfaces with $100M, $1.2B Sanofi pact for redosable DNA medicines
    Backed by Novartis’ venture arm, Eli Lilly and CRISPR Therapeutics, Seawolf is advancing its nonviral DNA delivery platform while inking a pact with Sanofi.
    biospace · 1d ago
  • Big-name investors pour $100M into DNA therapeutics developer Seawolf
    The startup, which also just disclosed an up to $1.2 billion partnership with Sanofi, is backed by Versant, MPM BioImpact, Eli Lilly and Novartis’ venture arm.
    biopharma_dive · 1d ago
  • Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings
    When Ionis Pharmaceuticals’ Tryngolza undersold, investors immediately looked to Arrowhead Pharmaceuticals’ executives for answers on how they will navigate a launch in the same market.
    biospace · 3d ago
  • This week in charts: Brain drugs are back on venture capitalists’ minds
    Five neurology-focused startups have together raised around $450 million in the last few weeks. Elsewhere, investors had a muted response to the latest cell therapy research.
    biopharma_dive · 3d ago
  • Big Pharma-backed Seawolf surfaces with $100M to hand, $1.2B Sanofi DNA med pact
    Seawolf Therapeutics has emerged from the deep with $100 million to fuel its DNA therapeutic ambitions and a billion-dollar deal with Sanofi.
    fiercebiotech · 4d ago
  • Beam’s base editing therapy for sickle cell hits goal in pivotal trial
    The result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.
    biopharma_dive · 6d ago
  • Beam preps FDA run for industry-first base-edited therapy after pivotal sickle cell success
    Beam Therapeutics' risto-cel provided at least 12 consecutive months of freedom from severe pain crises for patients with sickle cell disease in a mid-stage trial, setting the stage for an FDA appl…
    biospace · 6d ago
  • Beam’s sickle cell therapy results tee up potential Casgevy, Lyfgenia showdown
    Gearing up for a potential FDA filing by the end of the year, Beam Therapeutics revealed results from a phase 1/2 study of its base-edited cell therapy risto-cel, showing the potential sickle cell…
    fiercebiotech · 6d ago
  • Plug-and-play gene therapy: FDA executes on vision that’s been in the works for years
    Former biologics boss Peter Marks had a vision. With the FDA’s latest draft guidance, it’s coming to fruition. Speaking with BioSpace, current CBER leader Karim Mikhail said the “adapted pathway” i…
    biospace · 15d ago
  • Most new drugs are still too costly at launch, ICER says
    A new analysis from the non-profit group found that net launch prices for new medicines spiked significantly between 2022 and 2025, and the majority were well above its cost-effectiveness guidelines.
    biopharma_dive · 27d ago
view all news mentions →
identifiers
ticker
$CRSP
SEC CIK
0001674416
country
CH
source
sec_tickers
top tags
DLBCL1Oncology1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 39m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?